header header

PREIMPLANTATION GENETIC DIAGNOSIS FOR BRCA 1/2 CARRIERS

x
A
Assisted Embryo Hatching

a procedure in which a hole is made in the zona pellucida of the early embryo. The embryo may more easily “hatch” out of the zona through the hole prior to implantation.

Assisted Reproductive Technologies (ART)

a collective term which refers to a variety of medical procedures used to achieve pregnancy.

B
Blastocyst

the stage of development that the embryo is in when it enters the uterine cavity for implantation (typically 5-6 days after fertilization). It is comprised of two types of cells; an outer layer of cells called the trophoblast that will become the supporting tissue of the embryo such as the placenta and an inner layer referred to as the Inner Cell Mass, which will be multiply and contribute to the cells of the embryo.

Blastomere

a single cell from the developing 3-day embryo.

C
Cryopreservation

halting the embryo development before implantation through a freezing procedure.

Controlled Ovarian Hyperstimulation (COH)

the use of medications to stimulate growth and development of multiple ovarian follicles.

F
Follicle

a structure in the ovary that has nurtured the ripening egg and from which the egg is released or retrieved.

Follicle Stimulating Hormone (FSH)

a hormone produced by the pituitary gland that stimulates the ovary to ripen a follicle for ovulation.

Fluorescent in-situ hybridization (FISH)

a type of visualization used to determine the chromosome number and chromosomal mutation status of the embryo via PGD or PND.

G
Genetic counselor

a medical professional with specialized training in clinical genetics.

I
Intracytoplasmic Sperm Injection (ICSI)

an assisted fertilization technique in which a sperm is micro injected directly into the egg cytoplasm.

In Vitro Fertilization (IVF)

a procedure during which an egg is removed from a ripe follicle and fertilized by a sperm outside the human body.

L
Linkage Analysis

involves the study of BRCA1/2 inheritance patterns within a family and the identification of genetic markers that map near the gene. These genetic markers are physically linked to the gene.

M
Meiosis

this term describes cell division that occurs during the formation of the mature egg and sperm. During meiosis, the number of chromosomes (genes) is reduced so that the egg and sperm contribute only half of the parent’s genes to the embryo.

O
Ovarian Hyperstimulation Stimulation Syndrome (OHSS)

a medical complication of the stimulation procedures and medications in which stimulated follicles produce excess hormones and other factors which may lead to serious complications and may cause cancellation of a cycle and for a small number of women may result in death.

P
Polar body

a polar body is a small cell that is naturally released by the egg or oocyte during the process of meiosis. The first polar body is released by the oocyte near the time of ovulation. The second polar body is released by the oocyte, at the time of fertilization. The polar bodies do not contribute to the developing embryo, but are naturally discarded by the oocyte during the process of meiosis. Because the polar body contains one half of the possible genetic information of the mother, the genetic information of the oocyte can be inferred by the genetic testing of the polar body.

Polymerase chain reaction (PCR)

one of the most widely used laboratory techniques for visualizing genetic information and can be used for PGD or PND.

Preimplantation Genetic Diagnosis (PGD)

refers to procedures that are performed on embryos prior to implantation, sometimes even on oocytes prior to fertilization to determine gene status.

Prenatal Diagnosis (PND)

testing for genetic mutations in a fetus during the first or second trimester of pregnancy.

x

A Visual Guide to BRCA and PGD:

The following graphic represents the different stages of the IVF, PGD, and PND procedures. The outer circle shows the order of the stages, an explanation and the approximate time span. The inner circle holds a visual representation of the procedure.
The "+" in the graphic refers to the procedure being successful; the "–" refers to the procedure being unsuccessful.

BRCA PGD infographic

Social Considerations:

Many people are surprised to learn that in the United States, diagnostic genetic tests are not approved by the FDA. However, because many genetic diagnostic tests are patented, industry voluntarily self-regulates by assuring that tests meet good manufacturing practices (GMP) and the standards of CLIA (Clinical Laboratory Improvement Amendments). Thus, in the United States, genetic tests are not approved by the FDA, but may meet CLIA and GMP criteria.

PGD is a medical procedure that involves a genetic test, but like other medical procedures such as surgery does not fall under FDA regulation and oversight. Thus, PGD undergoes "professional self-regulation," which means that professional societies, composed of genetic counselors (National Society of Genetic Counselors--NSGC) and fertility clinicians (American Society for Reproductive Medicine--ASRM) reach an agreement on which procedures are appropriate and issue guidelines for practice.

Because health insurance companies in the United States usually approve procedures, medications, and tests that are covered by state-funded health programs such as Medicaid, and because most of those are FDA approved, PGD is not presently covered by Medicaid. Thus, PGD is usually not covered by health insurance, but IVF may be.